Scientists discovered that certain cancer cells use a low-level activation of a DNA-dismantling enzyme—normally seen in cell ...

Gene therapy could be a permanent cure for many life-threatening hereditary diseases, and this will only help in the treatment of genetic diseases and cancer ...

Discover why Denali Therapeutics Inc. earns a Strong Buy with FDA-priority drugs, solid pipeline, and a strong cash position.

Scientists from Kolkata-based Bose Institute have created GlowCas9--a CRISPR protein that lights up while performing gene ...

Is your favorite celebrity getting NAD+ therapy — and should you be too? The answer: maybe, but more research is needed to know for sure. NAD+, or nicotinamide adenine ...

Hearing scheduled for Scripps Park sidewalk widening A city of San Diego hearing officer is scheduled to consider plans to ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. | Pfizer has rolled out detailed trial ...

Servier India to launch Vorasidenib (Voranigo), a targeted therapy for patients with Grade 2 IDH-mutant glioma ...

The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The ...

Mirum is acquiring Bluejay Therapeutics for up to US$820 million to gain global rights to brelovitug, a late-stage monoclonal antibody for hepatitis D, aiming for potential approval in 2027. The deal ...